UVA Health Study Examines 972 Patients Treated With Sound Waves for Liver Tumors
A noninvasive treatment using focused sound waves can destroy liver tumors without an incision or a hospital stay, but real-world outcomes show that 11% of patients died within 30 days of the procedure, SciTechDaily reported. Researchers at UVA Health examined records from 972 patients treated with histotripsy between 2023 and 2026 to evaluate procedural safety against patient survival and disease burden. While the technology demonstrated low rates of laboratory toxicity and procedural complications, the findings indicate that patient selection and cancer stage heavily influence whether individuals live long enough to benefit from the therapy.
Evaluating Procedural Safety Versus 30-Day Mortality Rates
Histotripsy works by directing focused sound waves into diseased liver tissue to create air bubbles that mechanically destroy cancer cells. Following early clinical trials that established procedural safety and technical effectiveness, the U.S. Food and Drug Administration cleared the technology in 2023. To test those results in broader clinical practice, a research team led by Allan Tsung, MD, chair of UVA Health’s Department of Surgery, reviewed data from 972 patients treated through 2026. The analysis tracked survival outcomes alongside kidney injury risks and liver function before and after the outpatient procedure.
The data confirmed low levels of procedural complications and laboratory toxicity, supporting the physical tolerability of the sound-wave therapy. However, the 30-day mortality rate of 11% created an unexpected contrast for the surgical team. Tsung noted that while the figures do not prove histotripsy caused the deaths, they highlight a critical need to identify which patients possess the appropriate cancer type and life expectancy to gain meaningful clinical value from the intervention.
Metastatic Disease Limits Utility of Localized Liver Treatment
Nearly 70% of the histotripsy procedures analyzed in the UVA Health study involved patients whose cancer had spread to the liver from other parts of the body, including diagnoses such as pancreatic cancer. For individuals living with advanced metastatic disease, localized destruction of liver tumors offers limited utility if primary cancers continue to progress elsewhere. Consequently, researchers argue that treatment timing requires careful evaluation when advanced disease leaves minimal time for localized therapies to alter overall survival. Broad clinical data from national databases indicate that patients diagnosed with imminently fatal or de novo metastatic cancers face complex treatment planning driven by symptom burden, performance status, and access to care.
Frequently Asked Questions About Histotripsy
What is histotripsy and how does it destroy liver tumors?
Histotripsy is a noninvasive, outpatient treatment that uses focused sound waves directed at diseased liver tissue. The sound waves generate air bubbles that physically break down and destroy cancer cells without requiring surgical incisions.
What did the UVA Health study discover about patient outcomes?
The study reviewed 972 patients treated with histotripsy between 2023 and 2026 and found low rates of procedural complications and laboratory toxicity. However, researchers also recorded an 11% mortality rate within 30 days of the procedure, largely among patients with advanced metastatic cancers.
Why do nearly 70% of treated patients have metastatic cancer?
The majority of individuals undergoing the procedure in the real-world data set had cancers that spread to the liver from other primary sites, such as the pancreas. This widespread disease burden limits the overall survival benefit that a localized liver treatment can provide.
Keep reading